Actively Recruiting
PET Tau - Neurodegenerative Disease Imaging
Led by University of Pennsylvania · Updated on 2025-10-15
300
Participants Needed
1
Research Sites
731 weeks
Total Duration
On this page
Sponsors
U
University of Pennsylvania
Lead Sponsor
A
Avid Radiopharmaceuticals
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET/CT). Tau has been shown to build up in the brains of patients with injury to brain cells. This study looks at neurodegenerative diseases such as frontotemporal degeneration (FTD).
CONDITIONS
Official Title
PET Tau - Neurodegenerative Disease Imaging
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants diagnosed with a neurodegenerative disease such as FTD, PPA, CBD, PSP, MCI, AD, PCA, PD, PDD, DLB, MSA, ALS, or FTD-ALS
- Participants aged 18 years or older
- Participants must provide written informed consent or have a legal representative consent if unable, with patient assent when possible
- Participants must be willing and able to comply with scheduled visits and imaging procedures
- Participants must be concurrently enrolled in the UNICORN (842873) protocol
- Healthy controls must be 18 years or older
- Healthy controls must provide written informed consent
- Healthy controls must be willing and able to comply with scheduled visits and imaging procedures
- Healthy controls must be concurrently enrolled in the UNICORN (842873) protocol
You will not qualify if you...
- Pregnant or breastfeeding women at the time of baseline PET/CT scan
- Inability to tolerate or contraindication to imaging procedures as determined by investigator or physician
- Any medical or psychological condition that compromises safety or study participation
- Clinically significant cardiovascular disease or abnormal ECG findings, per investigator discretion
- Evidence of major stroke or mass on MRI that interferes with PET scan analysis
- For healthy controls: pre-existing psychiatric conditions such as active depression, schizophrenia, or active anxiety
- For healthy controls: neurological conditions such as stroke, epilepsy, or head trauma
- For healthy controls: current use of psychoactive medications or substances
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
D
Dahlia Kamel
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here